HC Wainwright Issues Pessimistic Outlook for AQST Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Equities researchers at HC Wainwright reduced their Q2 2025 earnings per share (EPS) estimates for Aquestive Therapeutics in a note issued to investors on Thursday, May 15th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.22) per share for the quarter, down from their previous estimate of ($0.15). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Aquestive Therapeutics’ Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.82) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.17) EPS and FY2026 earnings at ($0.75) EPS.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The business had revenue of $8.72 million during the quarter, compared to analyst estimates of $12.23 million.

Other research analysts have also issued research reports about the company. Raymond James set a $7.00 price target on Aquestive Therapeutics in a report on Friday, March 7th. Lake Street Capital dropped their target price on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Finally, Alliance Global Partners restated a “buy” rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $10.67.

Aquestive Therapeutics Stock Performance

Shares of NASDAQ:AQST opened at $2.45 on Monday. The business’s 50 day simple moving average is $2.75 and its two-hundred day simple moving average is $3.32. The firm has a market cap of $243.35 million, a P/E ratio of -5.44 and a beta of 2.02. Aquestive Therapeutics has a 52-week low of $2.12 and a 52-week high of $5.80.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of AQST. Summit Wealth & Retirement Planning Inc. bought a new position in shares of Aquestive Therapeutics in the first quarter valued at approximately $29,000. Victory Capital Management Inc. bought a new stake in Aquestive Therapeutics during the first quarter worth $31,000. Cambridge Investment Research Advisors Inc. bought a new stake in Aquestive Therapeutics during the first quarter worth $33,000. New York State Common Retirement Fund lifted its holdings in Aquestive Therapeutics by 713.3% during the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock worth $43,000 after acquiring an additional 10,700 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Aquestive Therapeutics during the fourth quarter worth $44,000. Institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.